An Open Label,Non-randomized,Prospective Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars in Healthy Volunteers

Abstract

Introduction: Compositional variations among biosimilar enoxaparin could lead to a differential immunogenic response between these preparations. Methods: Enoxaparin (Clexane, n = 110) and a biosimilar version (Cutenox, n = 110) were administered to healthy volunteers in Brazil, 40 mg subcutaneous (SQ), daily, for 10 days. Blood was collected at baseline, days 1 and 10, and analyzed for antiheparin/PF4 antibody (AHPF4 antibodies) titers and subtypes by enzyme-linked-immunosorbent serologic assay (ELISA). Results: Low-molecular-weight heparin (LMWH) treatment resulted in AHPF4 antibodies generation, with differences on day 10 (P < .05). Antibody subtyping (immunoglobulin [Ig] G, IgA, IgM) demonstrated different profiles between LMWH with statistical significance for IgG (Clexane 10 = 0.21 ± 0.06, Cutenox 10 = 0.28 ± 0.10, P < .0001) and IgA (Clexane 10 = 0.15 ± 0.02, versus Cutenox 10 = 0.13 ± 0.02, P < .0001) on day 10, with a significant drug effect (P < .0001) and significant time by drug interaction (P = .0009). All antibody titers were stated in terms of optical density (OD) units. Conclusion: LMWHs immunogenic potential varies to generate AHPF4 antibodies and subtypes and cross-reactivity with preformed antibodies. Such parameters may be useful in defining the biosimilar LMWHs bioequivalence. Future studies evaluating the immunogenicity of biosimilar drugs are warranted.

Keywords

immunogenicity antibody low-molecular-weight heparin platelet factor 4 thrombocytopenia

References

Gray E. , Mulloy B. Biosimilar low molecular weight heparin products. J Thromb Haemost. 2009;7(7):1218-1221.

Warkentin TE HIT: lessons learned. Pathophysiol Haemost Thromb. 2006;35(1-2):50-57.

Untch B. , Ahmad S. , Messmore HL , et al. Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies. Thromb Res. 2002;106(2):149-156.

Haas S. , Breyer HG , Bacher HP , et al. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial). Int Angiol. 2006;25(4):335-342.

Ahmad S. , Haas S. , Hoppensteadt DA , et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res. 2002;108(1):49-55.

Kannan M. , Saxena R. , Adiguzel C. , Fareed J. An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients. Semin Thromb Hemost. 2009;35(3):337-343.

Adiguzel C. , Bansal V. , Litinas E. , et al. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Clin Appl Thromb Hemost. 2009; 15(2):145-151.

Adiguzel C. , Jeske WP , Hoppensteadt D. , Walenga JM , Bansal V. , Fareed J. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for biosimilar products. Clin Appl Thromb Hemost. 2009; 15(2):137-144.

Fareed J. , Jeske W. , Fareed D. , et al. Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Clin Appl Thromb Hemost. 2008;14(4):385-392.

10.

Jeske WP , Walenga JM , Hoppensteadt DA , et al. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of biosimilar versions of low-molecular-weight heparins. Semin Thromb Hemost. 2008;34(1):74-85.

11.

Fareed J. , Hoppensteadt DA , Fareed D. , et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost. 2008;34(1):58-73.

12.

Hoppensteadt DA , Fabbrini N. , Bick RL , Messmore HL , Adiguzel C. , Fareed J. Laboratory evaluation of the antiphospholipid syndrome. Hematol Oncol Clin North Am. 2008 ;22(1):19-32, v.

13.

Ahmad S. , Untch B. , Haas S. , et al. Differential prevalence of antiheparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis . Mol Cell Biochem. 2004;258(1-2):163-170.